A randomized clinical trial failed to demonstrate a clinical benefit of methylprednisolone in hospitalized COVID-19 patients. The preliminary report from the randomized RECOVERY clinical trial (NEJMJW Infect Dis Sep 2020 and N Engl J Med 2020 Jul 17; [e-pub]) demonstrated that 10 days of dexamethasone resulted in a mortality benefit in hospitalized COVID-19 patients, especially those on mechanical ventilation. Investigators at a referral center in Brazil have now performed a double-blind, randomized, placebo-controlled clinical trial evaluating the efficacy of a 5-day course of methylprednisolone (MP) at reducing the mortality of patients hospitalized with COVID-19.
展开▼
